Poster 24

Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis in Patients Not Adequately Controlled or Non-Eligible for Cyclosporine: A Placebo-Controlled, Randomized Phase 3 Clinical Study (Advantage)

Authors: Richard B Warren, Marjolein de Bruin-Weller, Athanasios Tsianakas, Abdallah Khemis, Jacek C Szepietowski, H Chih-Ho Hong, Clara Armengol, Meritxell Falqués, Helena Agell, Eric Massana, Esther Garcia Gil, Stephan Weidinger

<PREVIOUS POSTER | NEXT POSTER>

Poster 24